Heather Jacene, MD

Heather Jacene, MD

Contact Information

Office Phone Number








Clinical Director, Nuclear Medicine/PET-CT
Associate Program Director, Brigham and Women's Joint Program in Nuclear Medicine
Senior Physician
Associate Professor of Radiology, Harvard Medical School


Clinical Interests

Imaging, Inflammatory breast cancer, Lymphoma, Nuclear medicine, Radiotherapy with unsealed sources

Board Certification

  • Nuclear Medicine, 2004


  • Johns Hopkins University, Nuclear Medicine/PET-CT


  • Johns Hopkins University, Nuclear Medicine

Medical School

  • University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School


    • Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759. View in: Pubmed

    • Hepatobiliary Scintigraphy: A Case-based Review. Radiographics. 2023 09; 43(9):e220104. View in: Pubmed

    • Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol. 2023 09 20; 41(27):4433-4442. View in: Pubmed

    • Report on the PET/CT Image-Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer. J Nucl Med Technol. 2023 Sep; 51(3):204-210. View in: Pubmed

    • SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 09; 64(9):1417-1423. View in: Pubmed

    • COVID-19: Findings in nuclear medicine from head to toe. Clin Imaging. 2023 Jul; 99:10-18. View in: Pubmed

    • SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 02; 64(2):204-210. View in: Pubmed

    • Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. J Nucl Med. 2023 03; 64(3):349-350. View in: Pubmed

    • Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. Hemasphere. 2023 Feb; 7(2):e826. View in: Pubmed

    • PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 04; 50(5):1466-1486. View in: Pubmed

    • Interim FDG-PET/CT for Response Assessment of Lymphoma. Semin Nucl Med. 2023 05; 53(3):371-388. View in: Pubmed

    • Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2022 Nov; 22(11):1163-1175. View in: Pubmed

    • Higher SUVmax on FDG-PET is associated with shorter survival in adrenocortical carcinoma. Am J Surg. 2023 02; 225(2):309-314. View in: Pubmed

    • Key Factors to Attract More U.S. Diagnostic Radiology Residents into the Field of Nuclear Medicine and Molecular Imaging: A National Survey. Acad Radiol. 2023 04; 30(4):755-762. View in: Pubmed

    • 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2022 09; 50(3):203-204. View in: Pubmed

    • 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy. J Nucl Med Technol. 2022 09; 50(3):213-214. View in: Pubmed

    • Standard Adult Gastric Emptying Scintigraphy Criteria Is Applicable for Partial Meal Ingestion. Dig Dis Sci. 2023 02; 68(2):541-553. View in: Pubmed

    • SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2022 09 01; 29(9):533-544. View in: Pubmed

    • Imaging for Radiation Planning in Breast Cancer. Semin Nucl Med. 2022 09; 52(5):542-550. View in: Pubmed

    • Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Sci Adv. 2022 Apr 29; 8(17):eabl6339. View in: Pubmed

    • Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? J Clin Oncol. 2022 09 10; 40(26):3011-3014. View in: Pubmed

    • Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngol Head Neck Surg. 2022 Mar 01; 148(3):268-276. View in: Pubmed

    • Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination. Clin Nucl Med. 2022 Mar 01; 47(3):e281-e283. View in: Pubmed

    • Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. J Nucl Med. 2021 Dec; 62(Suppl 3):60S-72S. View in: Pubmed

    • Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. J Nucl Med. 2021 Dec; 62(Suppl 3):23S-35S. View in: Pubmed

    • MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. Acad Radiol. 2022 05; 29(5):637-647. View in: Pubmed

    • PET Imaging for Hematologic Malignancies. Radiol Clin North Am. 2021 Sep; 59(5):705-723. View in: Pubmed

    • Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. Am J Clin Oncol. 2021 09 01; 44(9):449-455. View in: Pubmed

    • Evidence-Based Best Practices: 18F-FDG PET Staging of Newly Diagnosed Breast Cancer. Clin Nucl Med. 2021 07 01; 46(7):569-570. View in: Pubmed

    • Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. Ann Nucl Med. 2021 Sep; 35(9):1066-1077. View in: Pubmed

    • Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers (Basel). 2021 Jun 06; 13(11). View in: Pubmed

    • Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5a-Dihydrotestosterone PET: A Pilot Study. J Nucl Med. 2022 01; 63(1):22-28. View in: Pubmed

    • Intercostal Brown Adipose Tissue on FDG PET/CT. AJR Am J Roentgenol. 2021 10; 217(4):1007. View in: Pubmed

    • FDG PET for Assessment of Autologous Stem Cell Transplantation. Semin Nucl Med. 2021 07; 51(4):380-391. View in: Pubmed

    • 2020 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. J Nucl Med. 2020 10; 61(10):17N-23N. View in: Pubmed

    • Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570. View in: Pubmed

    • ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol. 2020 08; 43(8):539-544. View in: Pubmed

    • Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat. 2020 Jun; 181(2):383-390. View in: Pubmed

    • Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867. View in: Pubmed

    • Extraprostatic Uptake of 18F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer. AJR Am J Roentgenol. 2020 03; 214(3):641-648. View in: Pubmed

    • Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. Clin Imaging. 2020 02; 59(2):100-103. View in: Pubmed

    • 2019 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. J Nucl Med. 2019 Oct; 60(10):13N-18N. View in: Pubmed

    • Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. Breast J. 2020 03; 26(3):384-390. View in: Pubmed

    • No delayed imaging or CCK administration is needed in most cases when bowel excretion does not occur but gallbladder fills promptly. Ann Nucl Med. 2019 Oct; 33(10):740-745. View in: Pubmed

    • Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116. View in: Pubmed

    • Extraosseous Colonic Uptake of 99mTc-MDP Associated With Iodinated Contrast CT. Clin Nucl Med. 2019 May; 44(5):414-416. View in: Pubmed

    • Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610. View in: Pubmed

    • Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clin Breast Cancer. 2019 04; 19(2):146-155. View in: Pubmed

    • 2018 SNMMI Highlights Lecture: General Nuclear Medicine. J Nucl Med. 2018 Oct; 59(10):7N-13N. View in: Pubmed

    • 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2018 Sep; 46(3):245-246. View in: Pubmed

    • Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. J Nucl Med Technol. 2018 Sep; 46(3):237-244. View in: Pubmed

    • Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088. View in: Pubmed

    • Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun. 2018 May; 39(5):417-422. View in: Pubmed

    • Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. Clin Genitourin Cancer. 2018 08; 16(4):e919-e926. View in: Pubmed

    • PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Semin Nucl Med. 2018 01; 48(1):37-49. View in: Pubmed

    • Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD?×?two cycles followed by FDG-PET/CT restaging and 20?Gy of involved-site radiotherapy. Leuk Lymphoma. 2018 06; 59(6):1384-1390. View in: Pubmed

    • Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316. View in: Pubmed

    • Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Mol Imaging Biol. 2017 06; 19(3):429-436. View in: Pubmed

    • The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2017 Sep; 24(9):2563-2569. View in: Pubmed

    • Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability. J Nucl Med. 2017 09; 58(9):1429-1434. View in: Pubmed

    • Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135. View in: Pubmed

    • Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 11 24; 128(21):2489-2496. View in: Pubmed

    • Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 04; 15(2):e289-e298. View in: Pubmed

    • Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016 Apr; 13(4):365-71. View in: Pubmed

    • Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13. View in: Pubmed

    • Systemic Immune Response to Vaccination on FDG-PET/CT. Nucl Med Mol Imaging. 2016 Dec; 50(4):358-361. View in: Pubmed

    • Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015; 4:30. View in: Pubmed

    • Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat. 2015 May; 151(1):225-32. View in: Pubmed

    • Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol. 2015 Aug; 22(8):2483-91. View in: Pubmed

    • Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015 Mar-Apr; 35(2):424-37. View in: Pubmed

    • Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. PET Clin. 2015 Apr; 10(2):207-25. View in: Pubmed

    • Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med. 2015 Jan; 45(1):66-80. View in: Pubmed

    • Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. 2014 Feb; 39(1):33-9. View in: Pubmed

    • Gynecologic oncologic imaging with PET/CT. Semin Nucl Med. 2014; 44(6):461-78. View in: Pubmed

    • Postradiation changes in tissues: evaluation by imaging studies with emphasis on fluorodeoxyglucose-PET/computed tomography and correlation with histopathologic findings. PET Clin. 2014 Apr; 9(2):217-35. View in: Pubmed

    • What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17. View in: Pubmed

    • Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective. AJR Am J Roentgenol. 2013 Oct; 201(4):801-10. View in: Pubmed

    • End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77. View in: Pubmed

    • Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013 Apr; 68(4):592-599. View in: Pubmed

    • PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology. AJR Am J Roentgenol. 2012 Aug; 199(2):W163-7. View in: Pubmed

    • PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease. AJR Am J Roentgenol. 2012 Aug; 199(2):W168-74. View in: Pubmed

    • Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54. View in: Pubmed

    • Molecular imaging training for nuclear medicine residents. J Nucl Med. 2012 Apr; 53(4):655-7. View in: Pubmed

    • Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4129-32. View in: Pubmed

    • Molecular imaging training course debuts. J Nucl Med. 2012 Jan; 53(1):16NA. View in: Pubmed

    • The relationship between patients' serum glucose levels and metabolically active brown adipose tissue detected by PET/CT. Mol Imaging Biol. 2011 Dec; 13(6):1278-83. View in: Pubmed

    • Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). J Clin Oncol. 2011 May 20; 29(15_suppl):8039. View in: Pubmed

    • Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec; 9(5):297-304. View in: Pubmed

    • Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010 Dec; 51(12):1878-84. View in: Pubmed

    • Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010 Sep; 17(9):1175-85. View in: Pubmed

    • Imaging of parathyroid glands. Otolaryngol Clin North Am. 2010 Apr; 43(2):399-415, x. View in: Pubmed

    • Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010 Mar; 51(3):368-75. View in: Pubmed

    • CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010 Feb; 51(2):246-50. View in: Pubmed

    • Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med. 2009 Nov; 50(11):1751-9. View in: Pubmed

    • Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009 Nov; 50(11):1760-9. View in: Pubmed

    • Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2009; 71(5):251-6. View in: Pubmed

    • The importance of brown adipose tissue. N Engl J Med. 2009 Jul 23; 361(4):417-8; author reply 419-20. View in: Pubmed

    • From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009 May; 50 Suppl 1:122S-50S. View in: Pubmed

    • Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. Med Phys. 2009 May; 36(5):1595-601. View in: Pubmed

    • [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 01; 27(16):2697-704. View in: Pubmed

    • Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009 Feb; 36(2):612-9. View in: Pubmed

    • Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009 Apr; 94(4):1310-6. View in: Pubmed

    • 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009 Jan; 50(1):8-17. View in: Pubmed

    • Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease. Clin Nucl Med. 2008 Dec; 33(12):909-11. View in: Pubmed

    • Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy. Otolaryngol Clin North Am. 2008 Dec; 41(6):1117-33, viii-ix. View in: Pubmed

    • Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med. 2008 Oct; 49(10):1620-7. View in: Pubmed

    • Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med. 2008 Oct; 49(10):1585-92. View in: Pubmed

    • Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 01; 26(25):4172-9. View in: Pubmed

    • Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2008 May 20; 26(15_suppl):8565. View in: Pubmed

    • Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008 Apr; 27(4):521-30. View in: Pubmed

    • Extramedullary hematopoiesis on F-18 FDG PET/CT in a patient with metastatic colon carcinoma. Clin Nucl Med. 2007 Nov; 32(11):878-80. View in: Pubmed

    • Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov; 48(11):1767-76. View in: Pubmed

    • Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging. 2008 Jan; 35(1):89-94. View in: Pubmed

    • Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg. 2007 Aug; 11(8):961-9; discussion 969. View in: Pubmed

    • Nuclear medicine training for radiology residents: needs assessment survey. Acad Radiol. 2007 Mar; 14(3):301-5. View in: Pubmed

    • Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med. 2006 Jul; 31(7):379-81. View in: Pubmed

    • Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006 Jun; 47(6):950-6. View in: Pubmed

    • The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Jan; 132(1):12-6. View in: Pubmed

    • Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecol Oncol. 2005 Sep; 98(3):510-2. View in: Pubmed

    • Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005 Jul-Aug; 25(4):1031-43. View in: Pubmed

    • F-18 FDG PET/CT in acute respiratory distress syndrome: a case report. Clin Nucl Med. 2004 Dec; 29(12):786-8. View in: Pubmed

    • 2-Deoxy-2-[18F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers. Mol Imaging Biol. 2004 Nov-Dec; 6(6):405-10. View in: Pubmed


    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Discovery and Insights